JP2010523156A - マイクロｒｎａによる癌患者における治療後生存の予測 - Google Patents

マイクロｒｎａによる癌患者における治療後生存の予測 Download PDF

Info

Publication number
JP2010523156A
JP2010523156A JP2010503183A JP2010503183A JP2010523156A JP 2010523156 A JP2010523156 A JP 2010523156A JP 2010503183 A JP2010503183 A JP 2010503183A JP 2010503183 A JP2010503183 A JP 2010503183A JP 2010523156 A JP2010523156 A JP 2010523156A
Authority
JP
Japan
Prior art keywords
hsa
expression level
patient
survival
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010503183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523156A5 (cg-RX-API-DMAC10.html
Inventor
チェン、ジアン−ウェイ
ユ、スン−リャン
チェン、シュアン−ユ
チャン、ギー−チェン
チェン、チー−イ
パン−チル ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DCB USA LLC
Original Assignee
DCB USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DCB USA LLC filed Critical DCB USA LLC
Publication of JP2010523156A publication Critical patent/JP2010523156A/ja
Publication of JP2010523156A5 publication Critical patent/JP2010523156A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010503183A 2007-04-10 2008-04-09 マイクロｒｎａによる癌患者における治療後生存の予測 Withdrawn JP2010523156A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91099307P 2007-04-10 2007-04-10
PCT/US2008/059767 WO2008124777A1 (en) 2007-04-10 2008-04-09 Predicting post-treatment survival in cancer patients with micrornas

Publications (2)

Publication Number Publication Date
JP2010523156A true JP2010523156A (ja) 2010-07-15
JP2010523156A5 JP2010523156A5 (cg-RX-API-DMAC10.html) 2010-09-16

Family

ID=39831416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503183A Withdrawn JP2010523156A (ja) 2007-04-10 2008-04-09 マイクロｒｎａによる癌患者における治療後生存の予測

Country Status (13)

Country Link
US (1) US7745134B2 (cg-RX-API-DMAC10.html)
EP (1) EP2134874A4 (cg-RX-API-DMAC10.html)
JP (1) JP2010523156A (cg-RX-API-DMAC10.html)
KR (1) KR20100027102A (cg-RX-API-DMAC10.html)
CN (1) CN101688240A (cg-RX-API-DMAC10.html)
AU (1) AU2008237036A1 (cg-RX-API-DMAC10.html)
CA (1) CA2695868A1 (cg-RX-API-DMAC10.html)
CO (1) CO6231056A2 (cg-RX-API-DMAC10.html)
IL (1) IL201298A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009010899A (cg-RX-API-DMAC10.html)
RU (1) RU2009141359A (cg-RX-API-DMAC10.html)
TW (1) TWI367949B (cg-RX-API-DMAC10.html)
WO (1) WO2008124777A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528659A (ja) * 2007-06-08 2010-08-26 アメリカ合衆国 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法
WO2013038737A1 (ja) 2011-09-16 2013-03-21 北海道公立大学法人 札幌医科大学 膀胱癌細胞の検出方法、膀胱癌細胞の検出方法に用いるプライマー及び膀胱癌マーカ
JP2015502176A (ja) * 2011-12-19 2015-01-22 ヴァリー ヘルス システム 癌を患うリスクのある被検体を診断するための方法およびキット
JP2021527874A (ja) * 2018-06-18 2021-10-14 インターナショナル・ビジネス・マシーンズ・コーポレーションＩｎｔｅｒｎａｔｉｏｎａｌ Ｂｕｓｉｎｅｓｓ Ｍａｃｈｉｎｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 生存イベントのジョイントモデリングによる潜在的ながん治療標的の決定

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016548A2 (en) 2005-08-01 2007-02-08 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
EP2484782B1 (en) 2006-01-05 2015-11-18 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
AU2007205234B2 (en) 2006-01-05 2012-07-12 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
ES2425387T3 (es) 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
JP2010516291A (ja) 2007-01-31 2010-05-20 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 急性骨髄性白血病（ａｍｌ）の診断、予後及び治療のためのマイクロｒｎａに基づく方法及び組成物
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
EP2173911B1 (en) 2007-07-31 2014-06-18 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009055773A2 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
US8729041B2 (en) 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
EP2196543A1 (en) * 2008-12-15 2010-06-16 Koninklijke Philips Electronics N.V. Compositions and methods for micro-rna expression profiling of hepatocellular cancer
WO2010094155A1 (en) * 2009-02-23 2010-08-26 Capitalbio Corporation Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival
CN101638656B (zh) * 2009-08-28 2011-05-11 南京医科大学 一种与非小细胞肺癌预后相关的血清/血浆miRNA标志物及其应用
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
MX342967B (es) * 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
US20110223607A1 (en) * 2010-03-12 2011-09-15 Quest Diagnostics Investments Incorporated Circulating microrna as a marker for hepatocellular carcinoma
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
JP2014509852A (ja) 2011-03-07 2014-04-24 ジ・オハイオ・ステート・ユニバーシティ マイクロＲＮＡ−１５５（ｍｉＲ−１５５）により誘導される変異誘発活性は炎症および癌を結び付ける
US8404437B2 (en) 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer
WO2012151212A1 (en) * 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
EP2790735A4 (en) 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
US10738363B2 (en) 2016-08-31 2020-08-11 National Central University Analyzer and analytical method for predicting prognosis of cancer radiotherapy
DE102018110526A1 (de) 2018-05-02 2019-11-07 Faurecia Autositze Gmbh Verfahren zur Montage eines Linearaktuators für einen Kraftfahrzeugsitz
CN108648826B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法
CN108320806B (zh) * 2018-05-09 2022-04-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的结肠癌个性化预后评估方法
CN108630317B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肝癌个性化预后评估方法
CN108733980B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 基于多基因表达特征谱胶质母细胞瘤个性化预后评估方法
CN108363907B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
CN108647493B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种肾透明细胞癌个性化预后评估方法
CN108470111B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胃癌个性化预后评估方法
CN108611416B (zh) * 2018-05-09 2020-12-29 中国科学院昆明动物研究所 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法
TWI758670B (zh) * 2018-12-24 2022-03-21 奎克生技光電股份有限公司 健康風險評估方法
CN111172285A (zh) * 2020-02-26 2020-05-19 江南大学附属医院 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用
TWI878107B (zh) * 2024-04-30 2025-03-21 朱旆億 乳癌預後存活率預測模型建立方法及系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029287A2 (en) * 2002-09-27 2004-04-08 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
ATE546528T1 (de) * 2002-11-13 2012-03-15 Univ Jefferson Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
EP1713938A2 (en) * 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
US20050272067A1 (en) * 2004-03-10 2005-12-08 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20060078913A1 (en) * 2004-07-16 2006-04-13 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528659A (ja) * 2007-06-08 2010-08-26 アメリカ合衆国 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法
WO2013038737A1 (ja) 2011-09-16 2013-03-21 北海道公立大学法人 札幌医科大学 膀胱癌細胞の検出方法、膀胱癌細胞の検出方法に用いるプライマー及び膀胱癌マーカ
JP2015502176A (ja) * 2011-12-19 2015-01-22 ヴァリー ヘルス システム 癌を患うリスクのある被検体を診断するための方法およびキット
JP2021527874A (ja) * 2018-06-18 2021-10-14 インターナショナル・ビジネス・マシーンズ・コーポレーションＩｎｔｅｒｎａｔｉｏｎａｌ Ｂｕｓｉｎｅｓｓ Ｍａｃｈｉｎｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 生存イベントのジョイントモデリングによる潜在的ながん治療標的の決定
JP7332173B2 (ja) 2018-06-18 2023-08-23 インターナショナル・ビジネス・マシーンズ・コーポレーション 生存イベントのジョイントモデリングによる潜在的ながん治療標的の決定

Also Published As

Publication number Publication date
EP2134874A1 (en) 2009-12-23
TWI367949B (en) 2012-07-11
WO2008124777A1 (en) 2008-10-16
CN101688240A (zh) 2010-03-31
AU2008237036A2 (en) 2010-09-09
AU2008237036A1 (en) 2008-10-16
KR20100027102A (ko) 2010-03-10
IL201298A0 (en) 2010-05-31
CA2695868A1 (en) 2008-10-16
TW200912002A (en) 2009-03-16
RU2009141359A (ru) 2011-05-20
US7745134B2 (en) 2010-06-29
MX2009010899A (es) 2010-02-17
US20080254473A1 (en) 2008-10-16
CO6231056A2 (es) 2010-12-20
EP2134874A4 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
CN101688240A (zh) 通过微rna预测癌症患者的治疗后存活预期
Lu et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer
Spahn et al. Expression of microRNA‐221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence
Hu et al. Serum MicroRNA signatures identified in a genome-wide serum MicroRNA expression profiling predict survival of non–small-cell lung cancer
Bagnoli et al. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
Hoppe et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment
Wach et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening
Yuan et al. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients
Komatsu et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma
JP7186700B2 (ja) 腫瘍抑制ｆｏｘｏ活性を酸化ストレスから区別する方法
Feber et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma
Li et al. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma
Schetter et al. Alterations of microRNAs contribute to colon carcinogenesis
Rahbari et al. Identification of differentially expressed microRNA in parathyroid tumors
Mearini et al. Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer
JP6704861B2 (ja) 癌処置のための個別化三剤治療を選択するための方法
Berghmans et al. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study
Shen et al. Applications of microRNAs in the diagnosis and prognosis of lung cancer
JP7043404B2 (ja) 早期乳癌における内分泌処置後の残留リスクの遺伝子シグネチャー
WO2014058394A1 (en) Method of prognosis and stratification of ovarian cancer
Sun et al. Screening of differently expressed miRNA and mRNA in prostate cancer by integrated analysis of transcription data
Ak et al. MicroRNA expression patterns of tumors in early-onset colorectal cancer patients
Odenthal et al. Serum micro RNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction
Greco et al. The potential role of microRNAs as biomarkers in benign prostatic hyperplasia: a systematic review and meta-analysis
Guan et al. Identification of low miR-105 expression as a novel poor prognostic predictor for human glioma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100727

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20110705